Compare Berkshire Hathaway Inc Class B (BRK.B) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Berkshire Hathaway Inc Class B vs Sanofi SA — how do they compare? Berkshire Hathaway Inc Class B trades at $509.6, while Sanofi SA trades at $43.61 (market cap $104.30B). The key difference: Sanofi SA pays a 5.55% dividend while Berkshire Hathaway Inc Class B pays none, and Berkshire Hathaway Inc Class B is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| BRK.B | SNY | |
|---|---|---|
Sector | Financials | Health |
52-Week High | $529.65 | $52.34 |
52-Week Low | $465.39 | $41.33 |
Market Cap | — | $104.30B |
Enterprise Value | — | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BRK.B trades at $510.23, down 3.67% today, with technical indicators showing a bullish trend from moving averages but neutral oscillators. Analyst consensus is positive with 57% buy ratings. The stock's fundamentals reflect Berkshire Hathaway's diversified holdings and strong cash flow, though specific valuation ratios are not provided in the snapshot.
The outlook remains favorable due to strong analyst support and technical momentum, but risks include market volatility and economic uncertainties. Investment opportunity lies in the company's robust business model, while caution is advised near current resistance levels.
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Berkshire Hathaway Inc Class B
Berkshire Hathaway is a holding company with diverse subsidiaries, primarily in insurance through Geico and its reinsurance groups. It reinvests profits into various industries, owning Burlington Northern Santa Fe (railroad), Berkshire Hathaway Energy, and major manufacturing, service, and retail businesses like Precision Castparts and Lubrizol. The company operates in a highly decentralized manner.
Read more on BRK.B →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
